• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

Women suffering from ADHD have to make a difficult choice on whether to keep or stop taking ADHD medication during pregnancy and breast-feeding. There isn't much information on how long-term exposure to these medications can affect the foetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological problems such as hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge that further high-quality research is needed.

Risk/Benefit Analysis

Pregnant women who use ADHD medications need to balance the benefits of taking them against the potential risks to the fetus. Doctors don't have the information needed to provide clear recommendations but they can provide information on benefits and risks that can assist pregnant women in making informed choices.

A study published in Molecular Psychiatry found that women who used ADHD medications during early pregnancy did not have an higher risk of fetal cardiac malformations or major birth defects that are structural. Researchers used a large population-based case control study to examine the prevalence of structural defects that were major in infants born to mothers who took stimulants during pregnancy. Clinical geneticists, pediatric cardiologists and other experts looked over the cases to ensure that the classification was accurate and to minimize any bias.

However, the researchers' study had its limitations. Most important, they were unable to separate the effects of the medication from the underlying disorder. This limitation makes it difficult for researchers to determine if the small differences observed between the groups that were exposed to the use of medications, or if they were confounded by comorbidities. Researchers also did not study long-term outcomes for the offspring.

The study revealed that infants whose mothers had taken ADHD medication during pregnancy were at a slightly higher chance of being admitted to the neonatal care unit (NICU) in comparison to those whose mothers did not use any medication during pregnancy or quit taking the medication prior to or during pregnancy. The reason for this was central nervous system-related disorders, and the increased risk of admission was not found to be influenced by the stimulant medication was used during pregnancy.

Women who took stimulant ADHD medication during pregnancy were also at an increased chance of having a caesarean section or having a child with an low Apgar score (less than 7). These increases didn't appear to be affected by the kind of medication used during pregnancy.

The research suggests that the low risk associated with the use of ADHD medications during early pregnancy may be offset by the greater benefits to both mother and child of continuing treatment for the woman's condition. Physicians should talk to their patients about this and try to help them develop coping skills that can lessen the effects of her disorder on her daily functioning and her relationships.

Medication Interactions

Doctors are increasingly confronted with the dilemma of whether to keep treatment or stop it during pregnancy as more women are diagnosed with ADHD. The majority of these decisions are taken in the absence of clear and authoritative evidence in either case, which means that doctors have to weigh their experience about their experiences, the experiences of other doctors, and what research suggests about the subject and their own judgments for each individual patient.

The issue of risk for infants can be extremely difficult. Many studies on this issue are based on observations rather than controlled research, and their findings are often contradictory. Most studies focus on live births, which may underestimate the severity of teratogenic effects which can cause abortions or terminations of pregnancy. The study discussed in this journal club addresses these limitations by examining data on both live and deceased births.

Conclusion: While some studies have revealed a positive correlation between ADHD medications and certain birth defects however, other studies haven't shown such a relationship. Most studies show a neutral, or even slight negative impact. In all cases an in-depth analysis of the potential risks and benefits is required.

It can be difficult, if not impossible for women suffering from ADHD to stop taking their medication. In a recent article in Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication for adhd and anxiety during pregnancy can cause depression, feelings of loneliness and family conflict for these patients. A decrease in medication could also impact the ability to drive safely and perform work-related tasks, which are vital aspects of everyday life for those suffering from ADHD.

She suggests that women who aren't sure whether to take the medication or stop it due to their pregnancy, educate their family members, coworkers and their friends about the condition, its effects on daily functioning, and the benefits of keeping the current treatment regimen. In addition, educating them can aid in ensuring that the woman feels supported when she is struggling with her decision. It is important to note that certain drugs can be absorbed through the placenta therefore, if a patient decides to stop her ADHD medication during pregnancy and breastfeeding, she should be aware that the effects of the medication could be transferred to the child.

Risk of Birth Defects

As the use and use of ADHD medications to treat the symptoms of attention deficit hyperactivity disorder (ADHD) is increasing as does the concern about the possible effects of the drugs on foetuses. A recent study published in the journal Molecular Psychiatry adds to the body types of adhd medication information on this topic. With two massive data sets researchers were able look at more than 4.3 million pregnancies and see whether the use of stimulant medications increased the risk of birth defects. While the overall risk remains low, the scientists did find that first-trimester exposure to ADHD medications was linked to an increase in the risk of certain heart defects, such as ventriculoseptal defect (VSD).

The researchers behind the study found no association between early use of medication and other congenital anomalies, such as facial clefting or club foot. The results are in agreement with previous studies which showed the existence of a slight, but significant increase in cardiac malformations for women who began taking ADHD medication before pregnancy. This risk increased during the latter part of pregnancy, when a lot of women are forced to stop taking their ADHD medications.

Women who took ADHD medications in the first trimester of their pregnancies were also more likely to undergo caesarean sections, a low Apgar score after delivery and a baby who needed help breathing at birth. However the authors of the study were not able to eliminate bias due to selection by restricting the study to women who didn't have any other medical issues that could have contributed to the findings.

Researchers hope that their study will help doctors when they see pregnant women. The researchers recommend that while discussing benefits and risks are important, the choice about whether to continue or stop medication should be made in light of the severity of each woman's ADHD symptoms and the needs of the woman.

The authors also advise that while discontinuing the medications is an option, it isn't an option that is recommended due to the high prevalence of depression and other mental health problems in women who are pregnant or who are recently post-partum. Further, research shows that women who stop taking their medication will have a tough adjustment to life without them after the baby is born.

Nursing

The responsibilities of being a new mom can be overwhelming. Women suffering from ADHD may face a lot of challenges when they must manage their symptoms, attend doctor appointments, prepare for the birth of a baby and adjust to a new routine. Therefore, many women choose to continue taking their ADHD medication throughout the pregnancy.

The risk to a nursing infant is low because the majority of stimulant medications passes through breast milk in low amounts. The rate of medication exposure will differ based on dosage, frequency of administration and time of day. In addition, various drugs enter the infant's system through the gastrointestinal tract or through breast milk. The effect on the health of a newborn isn't fully comprehended.

Some doctors may stop taking stimulant medications during a woman's pregnancy due to the lack of research. This is a complicated decision for the patient, who must weigh the benefit of continuing her medication against the potential dangers to the foetus. As long as more information is available, doctors may inquire about pregnant patients whether they have a history of ADHD or if they intend to take medication during the perinatal phase.

A increasing number of studies have shown that the majority of women are able to safely continue their ADHD medication during pregnancy and while breastfeeding. In the end, an increasing number of patients are choosing to do so and, in consultation with their physician, they have found that the benefits of maintaining their current medication outweigh any risks.

It is crucial for women suffering from ADHD who are considering breastfeeding to seek out a specialist psychiatrist's advice prior becoming pregnant. They should review their medications with their doctor and discuss the advantages and disadvantages of continuing treatment, including non-pharmacological strategies. Psychoeducation should also be offered to help pregnant people with ADHD understand their symptoms and underlying disorder Learn about the available treatment options and strengthen existing strategies for managing. This should be an approach that is multidisciplinary, including the GP, obstetricians and psychiatry. Pregnancy counseling should include discussion of a treatment plan for the mother and child, and monitoring for signs of deterioration, and, if necessary adjustments to the medication regime.